Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

KRYSTAL BIOTECH, INC.

(KRYS)
  Report
Delayed Nasdaq  -  04:00 2022-09-29 pm EDT
70.56 USD   -0.48%
09/29Krystal Biotech to Present atáChardan's 6th Annual Genetic Medicines Conference
AQ
09/22Krystal Biotech Says European Medicines Regulator Adopts Positive Opinion on Dystrophic Epidermolysis Bullosa Drug Candidate
MT
09/21Krystal Biotech Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for B-VEC for the treatment of Dystrophic Epidermolysis Bullosa
GL
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/23/2022 09/26/2022 09/27/2022 09/28/2022 09/29/2022 Date
67.69(c) 67.71(c) 69.15(c) 70.9(c) 70.56(c) Last
300 073 212 980 196 857 255 431 287 955 Volume
-4.18% +0.03% +2.13% +2.53% -0.48% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 1,24 M - -
Net income 2022 -143 M - -
Net cash position 2022 358 M - -
P/E ratio 2022 -13,4x
Yield 2022 -
Sales 2023 48,4 M - -
Net income 2023 -123 M - -
Net cash position 2023 243 M - -
P/E ratio 2023 -16,8x
Yield 2023 -
Capitalization 1 811 M 1 811 M -
EV / Sales 2022 1 174x
EV / Sales 2023 32,4x
Nbr of Employees 119
Free-Float 79,8%
More Financials
Company
Krystal Biotech, Inc. is a clinical-stage biotechnology company. The Company is focused on the development of redosable gene therapies for patients living with debilitating diseases. It has developed a gene delivery platform that enables off-the-shelf treatments for serious dermatology and respiratory diseases. Its platform consists of an engineered viral vector derived from the herpes simplex virus type 1 (HSV-1)... 
More about the company
Ratings of Krystal Biotech, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
D+
More Ratings
All news about KRYSTAL BIOTECH, INC.
09/29Krystal Biotech to Present atáChardan's 6th Annual Genetic Medicines Conference
AQ
09/22Krystal Biotech Says European Medicines Regulator Adopts Positive Opinion on Dystrophic..
MT
09/21Krystal Biotech Receives Positive Opinion from EMA Pediatric Committee on the Pediatric..
GL
09/21Krystal Biotech Receives Positive Opinion from EMA Pediatric Committee on the Pediatric..
AQ
09/21Krystal Biotech Receives Positive Opinion from EMA Pediatric Committee on the Pediatric..
CI
09/09Krystal Biotech to Present at H.C. Wainwright 24th Annual Global Investment Conference
AQ
09/08Krystal Biotech to Present atáH.C. Wainwright 24th Annual Global Investment Conference
AQ
08/26North American Morning Briefing: Cautious Open -2-
DJ
08/25Goldman Sachs Downgrades Krystal Biotech to Neutral From Buy; Price Target is $74
MT
08/18Krystal Biotech's Biologics License Application for Dystrophic Epidermolysis Bullosa Th..
MT
08/18Krystal Biotech, Inc. : Regulation FD Disclosure, Other Events, Financial Statements and E..
AQ
08/18FDA Accepts Krystal Biotech's Biologics License Application for Dystrophic Epidermolysi..
AQ
08/18US Food and Drug Administration Accepts Krystal Biotech’s Biologics License Applic..
CI
08/09Chardan Research Adjusts Price Target on Krystal Biotech to $130 From $137, Citing Q2 R..
MT
08/08Krystal Biotech : Announces Second Quarter 2022 Financial Results and Reports Updates on O..
PU
More news
News in other languages on KRYSTAL BIOTECH, INC.
09/22Krystal Biotech reçoit un avis positif de la part du Comité pédiatrique de l'EMA pour s..
09/22Krystal Biotech erhält positive Stellungnahme des Pädiatrieausschusses der EMA hinsicht..
09/22Krystal Biotech erhält positive Stellungnahme des Pädiatrieausschusses der EMA hinsicht..
09/21Krystal Biotech reçoit un avis positif du comité pédiatrique de l'EMA sur le plan d'inv..
08/18La demande de licence de produits biologiques de Krystal Biotech pour le traitement de ..
More news
Analyst Recommendations on KRYSTAL BIOTECH, INC.
More recommendations
ETFs positioned on KRYSTAL BIOTECH, INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
ALPS Medical Breakthroughs ETF - USD1.01%2.09%United_States
Virtus LifeSci Biotech Clinical Trials ETF - USD0.89%3.63%United_States
ETFs S&P Biotech ETF - Distributing - AUD0.6%0.66%-United_States
SPDR S&P Biotech ETF - USD0.58%-5.82%United_States
IShares Nasdaq US Biotechnology (D) - USD0.2%0.80%United_States
More ETFs positioned on KRYSTAL BIOTECH, INC.
Chart KRYSTAL BIOTECH, INC.
Duration : Period :
Krystal Biotech, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KRYSTAL BIOTECH, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 70,56 $
Average target price 102,25 $
Spread / Average Target 44,9%
EPS Revisions
Managers and Directors
Krish S. Krishnan Chairman, President & Chief Executive Officer
Suma M. Krishnan Chief Operating Officer & Director
George Chen Manager-Information Technology & CSV
Trevor Parry Senior Director-Scientific Affairs
Brittani Agostini Senior Manager-Clinical Operations
Sector and Competitors
1st jan.Capi. (M$)
KRYSTAL BIOTECH, INC.0.87%1 811
GILEAD SCIENCES, INC.-13.14%79 050
VERTEX PHARMACEUTICALS33.33%75 091
REGENERON PHARMACEUTICALS, INC.9.55%73 961
BIONTECH SE-48.18%32 467
WUXI APPTEC CO., LTD.-38.82%29 383